20^th Annual Pharma Middle East Congress

Dacarbazine (DZ) is single drug approved by US-FDA for the treatment of a type of skin cancer melanoma., slow response rate with severe toxicity which limits its market potential. In view this study designed for formulation, characterization and pharmacological evaluation of dacarbazine laden nanocream (DZC) for the treatment of melanoma. DZC prepared by oil-in-water emulsion technique by using DZP. Dacarbazine nanoparticle and its cream were characterized for shape size of particle, drug loading capacity, nanoencapsulation efficacy, zeta potential, Transmission Electron Microscopy (TEM), pH value, spreadability and viscosity, in vitro drug releasing capacity and its cytotoxic effect by using MTT assay. The particle size of DZNP and DZNC was 16.3±8.1 nm and 16.9±7.8 nm respectively. pH value and spreadability of nanoparticle cream were found to be 6.7±0.14 g cm/sec and 55.23±3.13 g cm/sec respectively. Nanoencapsulation efficiency and Drug loading capacity were 67.4±3.5% and 6.73 mg/10 mg respectively. From above results, it can be concluded that DZC can be effectively utilized for the treatment of melanoma.